Kwon, Mi-Kyung Nam, Ju-Ock Park, Rang-Woon Lee, Byung-Heon Park, Jae-Yong Byun, Young-Ro Kim, Sang-Yoon Kwon, Ick-Chan Kim, In-San 2024-01-20T23:04:52Z 2024-01-20T23:04:52Z 2021-09-03 2008-06 1535-7163 https://pubs.kist.re.kr/handle/201004/133449 We have designed a novel peptide, TK3, composed of three functional domains, a protein transduction domain, a TAT followed by three tandem repeats of a proapoptotic peptide, and a caspase-3 cleavage site, (KLAKLAK)(2)-DEVD. TK3 was able to transduce into cells and then activate caspase-3, which in turn cleaved TO to release additional (KLAKLAK)(2) peptides. (KLAKLAK)(2) was well transduced by TAT into tumor cells and was able to induce apoptosis in vitro and in vivo. TK3 also induced apoptosis and inhibited angiogenesis in endothelial cells. Further, direct injection of TK3 into established B16F10 melanoma tumors in C57BL/6 mice resulted in almost complete inhibition of the tumor growth. These results suggest that TK3 could be beneficial for the treatment of accessible tumors and used as an adjuvant for cancer therapy. English AMER ASSOC CANCER RESEARCH VIVO PROTEIN TRANSDUCTION IN-VIVO INTRACELLULAR DELIVERY TUMOR VASCULATURE TAT PROTEIN MOUSE CELLS INHIBITION BETA-IG-H3 INTEGRIN Antitumor effect of a transducible fusogenic peptide releasing multiple proapoptotic peptides by caspase-3 Article 10.1158/1535-7163.MCT-07-2009 1 MOLECULAR CANCER THERAPEUTICS, v.7, no.6, pp.1514 - 1522 MOLECULAR CANCER THERAPEUTICS 7 6 1514 1522 scie scopus 000256955900018 2-s2.0-49849101354 Oncology Oncology Article VIVO PROTEIN TRANSDUCTION IN-VIVO INTRACELLULAR DELIVERY TUMOR VASCULATURE TAT PROTEIN MOUSE CELLS INHIBITION BETA-IG-H3 INTEGRIN